SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular risk partly through anti-inflammatory mechanisms—lowering cytokines, oxidative stress, and endothelial dysfunction beyond their glucose-lowering effects.
Beyond glucose loweringMultiple anti-inflammatory pathways explain the cardiovascular benefits of SGLT2i and GLP-1 RAs
What the researchers found
Both SGLT2i and GLP-1 RAs exert cardiovascular protection through multiple anti-inflammatory pathways including cytokine reduction, oxidative stress mitigation, immune modulation, and endothelial function improvement.
Why it matters
Understanding why these diabetes drugs protect the heart—beyond blood sugar control—could enable their use in non-diabetic cardiovascular disease and guide development of more targeted therapies.
How the study worked
Descriptive literature review of anti-inflammatory mechanisms of SGLT2 inhibitors and GLP-1 receptor agonists.
What this study cannot tell us
Descriptive review without systematic methodology. Many mechanistic studies are preclinical; clinical translation of individual anti-inflammatory pathways is not fully established.
How to read the evidence
Descriptive review of mechanistic literature; mixes preclinical and clinical evidence without systematic quality assessment.
When this study was published
Published in 2026, reviewing current literature.
The bigger picture
This review supports the paradigm shift from viewing diabetes drugs as merely glucose-lowering to recognizing them as broad cardiometabolic therapeutics with anti-inflammatory properties.
Questions still open
- Which specific anti-inflammatory pathways are most important for cardiovascular protection?
- Could these drugs benefit heart disease patients without diabetes by targeting inflammation?
- Do SGLT2i and GLP-1 RAs have additive anti-inflammatory effects when combined?
Common questions
How do diabetes drugs reduce inflammation?
Do you have to have diabetes to benefit from these anti-inflammatory effects?
Read the original research
Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review.
In vivo (Athens, Greece), 40(1), 600-627
Citation
Comșa, Adina David; Comșa, Horațiu; Cismaru, Gabriel; Roșu, Radu; Pop, Dana. (2026). Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review.. In vivo (Athens, Greece), 40(1), 600-627. https://doi.org/10.21873/invivo.14224